EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

H3K18la Facilitates TRA2A-Mediated Alternative Splicing of STIL, Suppressing Ferroptosis and Cisplatin Treatment Sensitivity in Ovarian Cancer

Mingyang Gao, Shiming Wang, Zhiyuan Huang, Tianliang Wang, Yuexin Yu

Cancer Research and Treatment · 15.10.2026 · 58 (4) · 1428-1448

DOI: 10.4143/crt.2025.752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.10.2026. Verfasst von Mingyang Gao und 4 weiteren Autor:innen. Beteiligte Einrichtung: General Hospital of Northern Theater Command, Shenyang, China. Hauptthemen laut MEDLINE: Cisplatin, Ovarian Neoplasms, Ferroptosis, Alternative Splicing. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Ovarian cancer (OC) is a common and highly lethal malignant tumor in women. Due to its hidden early symptoms, most patients are diagnosed at an advanced stage, and the tumor often develops resistance to chemotherapy, making treatment challenging. Elucidating the mechanisms of OC development and identifying new therapeutic targets are crucial for improving treatment outcomes.Materials and Methods We used bioinformatics analysis combined with quantitative real-time polymerase chain reaction, western blot, and immunohistochemistry to study transformer 2 alpha (TRA2A) expression and histone lactylation in OC samples. Cell Counting Kit-8, colony formation, 5-ethynyl-2’-deoxyuridine, and Transwell experiments were used to assess OC cells proliferation. Reverse transcription polymerase chain reaction analyzed TRA2A-mediated alternative splicing (AS). And the nude mouse xenograft model was constructed to validate TRA2A’s molecular function in vivo.

Results

This study reveals a novel mechanism by which OC cells evade ferroptosis through the TRA2A-STIL signaling axis. Specifically, H3K18la is significantly enriched at the promoter region of the TRA2A gene, activating its transcription and upregulating expression. The upregulated TRA2A protein, functioning as a key splicing factor, specifically regulates AS of the STIL mRNA. This promotes expression of the STIL-L isoform, which inhibits ferroptosis in OC cells by modulating iron metabolism. Furthermore, targeted knockdown of TRA2A combined with cisplatin treatment significantly enhanced the therapeutic efficacy against OC. Consequently, targeting TRA2A-mediated AS represents a promising novel therapeutic target for OC.

Conclusion

This study uncovers for the first time a novel mechanism by which OC cells evade ferroptosis via an H3K18la-modified TRA2A-STIL signaling axis, thereby establishing a promising new therapeutic target for OC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinOvarian NeoplasmsFerroptosisAlternative SplicingHistonesRNA-Binding ProteinsSerine-Arginine Splicing FactorsFemaleHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysGene Expression Regulation, NeoplasticMice, NudeDrug Resistance, NeoplasmCell Proliferation

Stichwörter der Autor:innen

Alternative splicingFerroptosisH3K18laOvarian neoplasmsTRA2A

Substanzen

CisplatinHistonesRNA-Binding ProteinsSerine-Arginine Splicing Factors

Autor:innen und Institutionen

  • General Hospital of Northern Theater Command, Shenyang, China.
  • Liaoning Cancer Hospital and Institute, Shenyang, China.
  • Affiliated Central Hospital of Shenyang Medical College, Shenyang, China.
  • Xinmin People's Hospital, Jiangmen, China.
  • General Hospital of Northern Theater Command, Shenyang, China. yuyuexinszyx@163.com.

Zitieren

APA

Gao, M., Wang, S., Huang, Z., Wang, T., & Yu, Y. (2026). H3K18la Facilitates TRA2A-Mediated Alternative Splicing of STIL, Suppressing Ferroptosis and Cisplatin Treatment Sensitivity in Ovarian Cancer. Cancer Research and Treatment, 58(4), 1428-1448. https://doi.org/10.4143/crt.2025.752

Vancouver

Gao M, Wang S, Huang Z, Wang T, Yu Y. H3K18la Facilitates TRA2A-Mediated Alternative Splicing of STIL, Suppressing Ferroptosis and Cisplatin Treatment Sensitivity in Ovarian Cancer. Cancer Research and Treatment. 2026;58(4):1428-1448. doi:10.4143/crt.2025.752

BibTeX
@article{Gao2026,
  author = {Gao, Mingyang and Wang, Shiming and Huang, Zhiyuan and Wang, Tianliang and Yu, Yuexin},
  title = {H3K18la Facilitates TRA2A-Mediated Alternative Splicing of STIL, Suppressing Ferroptosis and Cisplatin Treatment Sensitivity in Ovarian Cancer},
  journal = {Cancer Research and Treatment},
  year = {2026},
  volume = {58},
  number = {4},
  pages = {1428--1448},
  doi = {10.4143/crt.2025.752}
}
Kostenlos starten →